NL-OMON48798尚未招募不适用
PROSPEC study; PROstate cancer follow-up care in Secondary and Primary hEalth Care - PROSPEC study
ederlands Kanker Instituut0 个研究点目标入组 390 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 390
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Men diagnosed with invasive prostate cancer;
- •- Stage cT1a - cT3; pNx - pN1; R0-1 having completed primary treatment
- •(prostatectomy or radiotherapy);
- •- Radiotherapy with or without androgen deprivation therapy (ADT) for localized
- •prostate cancer
- •- No evidence of recurrence (PSA<0.1 ng/ml after prostatectomy or PSA<
- •nadir+2.0 ng/mL after radiotherapy).
排除标准
- •- Primary treatment (prostatectomy, radiotherapy) completed longer than 6
- •months previously;
- •- Patients under active surveillance;
- •- Under investigation for possible recurrence (patients become eligible if
- •recurrence is ruled out);
- •- Does not have a community-based GP to provide care;
- •- Unable to comply with study protocol including completion of questionnaires;
- •- Actively followed by a cancer specialist for another primary cancer;
- •- (Previously) enrolled in a study requiring ongoing follow-up by a cancer
- •specialist;
- •- Serious (treatment related) toxicity that requires treatment;
- •- Patients that cannot sign informed consent or are unable to understand Dutch.
研究者
相似试验
招募中
不适用
PROstate cancer follow-up care in Secondary and Primary hEalth Care: PROSPEC study.Prostate cancer, survivorship, primary care, secondary care, follow-up, general practitioner, randomised controlled trialDutch: Prostaatcarcinoom, overlevingszorg, eerstelijnszorg, tweedelijnszorg, nazorg, huisarts, gerandomiseerd gecontroleerde trial.NL-OMON24717Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, The Netherlands390
未知
不适用
Follow-up study for localized prostate cancer treated by hormonal therapy or radical prostatectomy.Prostate cancerJPRN-UMIN000000570J-CaP study group2,000
已完成
不适用
A Study to Observe Demography and the Outcome of Prostate Cancer Patients Treated With 6-month Triptorelin Formulation in ItalyProstate CancerNCT05759273Ipsen167
进行中（未招募）
1 期
Study on patients with recurrence of prostate cancer with PET/MRRadically treated patient for prostate cancer presenting a biochemical recurrence of disease (PSA: > o = 0.2 ng/mL)MedDRA version: 21.1Level: LLTClassification code 10026389Term: Malignant neoplasm of prostateSystem Organ Class: 100000004864EUCTR2018-001036-21-ITOSPEDALE SAN RAFFAELE60
已完成
2 期
Non-systemic Treatment for Patients With Low-volume Metastatic Prostate CancerProstate CancerNCT01558427University Hospital, Ghent62